Findings from the PATRO Children study support the use of a biosimilar formulation of recombinant human growth hormone (somatropin) in children with Turner’s syndrome.
Researchers have found a large variety of genetic diagnoses in children with short stature investigated for suspected growth hormone insensitivity.
Researchers find that teenagers with endocrine disorders often have gaps in their knowledge of their condition and how to manage it, making them poorly prepared for transition to adult clinic.
A polygenic risk score for height can predict a child’s adult height with similar accuracy to their mid-parental height, say researchers.
Around 70% of children who survive a brain tumour develop at least one form of endocrine dysfunction, suggests a long-term study of patients attending a hospital in Portugal.
Collagenopathies could account for around one in 10 cases of familial short stature even when there are no obvious signs of dysplasia, say researchers.
A study of children with Noonan syndrome treated in clinical practice shows a good response to growth hormone treatment, with the majority achieving a height within population norms.
A longitudinal study of Finnish patients with juvenile acquired hypothyroidism has revealed that an abnormal growth pattern may be present for up to 5 years before diagnosis.
Children with idiopathic short stature and skeletal deformities should be tested for the NPR2 mutation, recommend Chinese researchers who believe that children with heterozygous mutations may benefit from recombinant human growth hormone therapy.
A single measurement of plasma levels of a fragment of type X collagen (Collagen X bioMarker) may give an instant picture of how fast a child is growing, say researchers.
